Loading
A phase 1/2 trial of U16 in non-Hodgkin lymphoma, run by Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, now recruiting.
Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma is a phase 1/2 interventional study registered as NCT05768529 by Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, with 100 participants planned, started 2023-03-28 and due to reach its primary completion in 2024-12-31. Interventions recorded: U16.
Shares Unicar-Therapy and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.